Navigation Links
Pharmaxis Research Programs Highlighted at European Respiratory Society Congress
Date:10/2/2008

SYDNEY, Australia, Oct. 3 /Xinhua-PRNewswire-FirstCall/ -- Pharmaceutical company Pharmaxis (ASX: PXS, NASDAQ: PXSL) has announced that researchers will present 12 abstracts from its respiratory disease program at the 2008 European Respiratory Society Congress (ERS) being held in Berlin from the 4th to the 8th October. The ERS brings together many of the world's top respiratory researchers and clinicians to hear latest advances in clinical diagnosis and treatment.

A comprehensive program of research will be presented in ERS symposiums and poster sessions relating to the lung challenge product, Aridol, and the mucus clearing agent, Bronchitol.

In a poster session Professor Di Bilton, Consultant Physician and Honorary Senior Lecturer at the Department of Respiratory Medicine, The Royal Brompton Hospital, London, UK, will detail results of a successful randomized, placebo- controlled trial of inhaled mannitol (Bronchitol) in patients with bronchiectasis.

Other key ERS program events from the Pharmaxis respiratory disease program include:

-- The use of inhaled mannitol (Aridol) for assessing airway disease

-- Direct versus indirect airway challenges

-- Using a dry powder of mannitol (Aridol) versus methacholine as

challenge for routine practice

-- Inhaled mannitol (Bronchitol) as treatment for children with cystic

fibrosis

-- Implications for everyday practice

-- Infectious lung diseases including tuberculosis

-- A randomized, placebo-controlled trial of inhaled

mannitol(Bronchitol) in patients with bronchiectasis

-- Cough and airway hyperresponsiveness

-- A comparison of inhaled mannitol (Aridol), methacholine

provocation and eucapnic voluntary hyperventilation as diagnostic

tests for exercised-induced bronchoconstriction in cross country

skiers

-- Assessment of inflamm
'/>"/>

SOURCE Pharmaxis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. New Pharmaxis Board Appointment
2. Pharmaxis Aridol Authorised for Sale in Germany
3. Pharmaxis First Steps into China
4. Pharmaxis to Apply to Market Bronchitol in Australia
5. Pharmaxis Investor Conference Call
6. Pharmaxis Aridol Gains First Asian Approval
7. Pharmaxis Appoints Portuguese Distributor for Aridol
8. Pharmaxis Closes Share Purchase Plan
9. Pharmaxis Announces Placement of $50 Million and Share Purchase Plan
10. Phase III Trial Finds Pharmaxis Bronchitol Effective
11. Halozyme Therapeutics to Host Research Day for Investors and Analysts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... +14% CER / 20% of sales) led the regional performance in the second ... well as solid contributions from Korea, India and ... East / Africa (Q2 2015: +3% CER ... Turkey and the United Kingdom . The ... HPV sales, on demand across all customer classes. The top seven emerging markets ...
(Date:7/29/2015)... College Station, TX (PRWEB) , ... July 29, ... ... cleanroom POD® designer, manufacturer and supplier, announces the launch of their 2nd generation ... compared to the current miniPOD CT, but it also represents a new POD® ...
(Date:7/29/2015)... 29, 2015  Therapath Neuropathology ( www.Therapath.com ), ... with VA and Military Medical centers both domestically ... (ENFD) and Sweat Gland Nerve Fiber Density (SGNFD) ... https://therapath.com/skin ). Demonstration of a ... on punch skin biopsy is a highly sensitive ...
(Date:7/29/2015)... VANCOUVER , July 29, 2015 /PRNewswire/ - RepliCel ... clinical stage regenerative medicine company, is pleased to announce ... dermal injector (RCI-02) have been locked.  Prototypes for ... to prepare for an application for CE mark ... Europe in 2016. (Photo: ...
Breaking Biology Technology:QIAGEN Reports Results for Second Quarter and First Half of 2015 2QIAGEN Reports Results for Second Quarter and First Half of 2015 3QIAGEN Reports Results for Second Quarter and First Half of 2015 4QIAGEN Reports Results for Second Quarter and First Half of 2015 5QIAGEN Reports Results for Second Quarter and First Half of 2015 6QIAGEN Reports Results for Second Quarter and First Half of 2015 7QIAGEN Reports Results for Second Quarter and First Half of 2015 8QIAGEN Reports Results for Second Quarter and First Half of 2015 9QIAGEN Reports Results for Second Quarter and First Half of 2015 10G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3Neuropathology services for VA and Military health systems 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 3RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 4RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 5
... ... Sepha Ltd has launched a new, mobile blister packing ... minimal cost. EZ BlisterII is a compact, easy to use ... response to global demand from major pharmaceutical and clinical trial laboratories for ...
... ESA,s Envisat has captured the changes in direction of the ... winds over the weekend pushed it around and hampered clean-up ... visible due east of the Delta National Wildlife Refuge extending ... ships. ,Wind can easily spread oil on the water, with ...
... from Stevens Institute of Technology, consisting of undergraduate ... Jing, Xi Chen, and Zhenbo Fu and led ... Shi from the Department of Mechanical Engineering, placed ... Institute of Standards and Technology (NIST) Mobile Microrobotics ...
Cached Biology Technology:New Mobile Blister Packing Technology Launched by Packaging Machinery Manufacturer, Sepha Ltd 2Envisat monitoring changes in oil spill 2Stevens team places third in 2010 IEEE/NIST Mobile Microrobotics Challenge 2
(Date:6/26/2015)... , June 26, 2015 ATL Technology, LLC, a ... with specialties in single use solutions, headquartered in ... Inc. (a California corporation with locations ... San Jose, Costa Rica ). This ... Rica with ATL Technology,s existing facility in ...
(Date:6/24/2015)... June 24, 2015 The biologics safety testing ... drivers for the market include growth of the pharmaceutical ... drug launches. Over the years, the number of drug ... and 2010, the FDA approved 225 drug applications and ... Europe accounted for 3,822 of ...
(Date:6/24/2015)... , June 24, 2015 Biometry ... with emerging biometric password solution one face in. ... one face in, entering the ... ground-breaking and affordable multifactor-authentication biometric answer to the ... technology, provided in partnership with KeyLemon, one face ...
Breaking Biology News(10 mins):ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... UK, the Charit University Medical School and the Max ... Germany, have discovered a new driving force behind cancer ... promotes the growth of cancer cells in patients with ... Dr Stephan Mathas (Charit, MDC) who co-led the study ...
... is no known cause of autism, studies have shown ... developmental brain disorder. New research has uncovered two additional ... will present their findings on Sunday, May 2 at ... British Columbia, Canada. An estimated one in 110 ...
... prevent ulcerative colitis, according to a new study co-ordinated by ... Presented today at the Digestive Disease Week conference in ... rich in oleic acid which is present in olive ... acid is a monounsaturated fatty acid found in olive oil, ...
Cached Biology News:'Junk DNA' drives cancer growth 2Study adds to evidence that autism has genetic basis 2Olive oil could guard against developing ulcerative colitis 2
...
... is a direct antibiotic-based selection system for ... colony survival, eliminating the need for costly ... provides close to 100% accuracy in recombinant ... for robot colony picking. This cloning kit ...
... is a direct antibiotic-based selection system for ... colony survival, eliminating the need for costly ... provides close to 100% accuracy in recombinant ... for robot colony picking. This cloning kit ...
... PCR plate, Directly compatible with ABI thermal ... for improved sealing characteristics can be ... or cap strips, Certified free of DNase, ... part of Thermo Fisher Scientific, the world ...
Biology Products: